4basebio Plc - 4basebio client's Phase I clinical trials for opDNA™ based mRNA vaccine
("4basebio" or the "Company")
4basebio announces key milestone with its client progressing into Phase I clinical trials of an
mRNA vaccine manufactured from 4basebio’s opDNA™
4basebio will continue to support HelixNano with the manufacture of GMP synthetic DNA planned for later in 2024.
Dr
“4basebio has several clients requiring GMP grade DNA and progressing towards clinical trials; we are of course very pleased to be supporting our clients in their clinical programs.”
Dr
For further enquiries, please contact:
4basebio PLC +44 (0)12 2396 7943Heikki Lanckriet Nominated Adviser Cairn Financial Advisers LLP +44 (0)20 7213 0880 Jo Tuner /Sandy Jamieson BrokerCavendish +44 (0)20 7220 0500Geoff Nash /Charlie Beeson /Nigel Birks Lionsgate Communications (Media Enquiries) +44 (0)77 91892509Jonathan Charles
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients. The company is offering GMP compliant DNA starting materials suitable for use in AAV viral vector production as well as mRNA vaccine and therapeutics production.
About
Forward-looking statements
This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.